AI help for tobacco and nicotine businesses

The category is shifting from a cigarette-led model toward a multi-category tobacco and nicotine portfolio

BAT reported that New Category revenue grew 18.0% in the first half of 2026, driven by Modern Oral and Vapour, with Modern Oral becoming its largest New Category by revenue. PMI reported that 42% of its global net revenues came from its smoke-free business in H1 2026. Independent UK evidence also shows adult nicotine-pouch use rising from a low base while vaping remains established, and new UK rules now regulate tobacco, vaping and nicotine products as distinct but overlapping categories. The strategic implication is that the operating model now needs to manage several regulated product architectures at once rather than treating the sector as cigarettes plus extensions.

Source: BAT H1 2026 Report; PMI Q2 2026 Results; ASH 2026 nicotine and vaping data; GOV.UK Tobacco and Vapes Act 2026 guidance

Why this vertical is under pressure

Legacy combustible tobacco remains economically material, but growth and innovation are increasingly concentrated in vaping, heated tobacco, oral nicotine and other newer nicotine formats. Each category can carry different product definitions, technical evidence, age controls, packaging, notification, excise, device, ingredient, traceability and retail requirements. At the same time, illicit supply, youth access concerns, changing tax regimes and rapid product cycles increase compliance complexity. The defensible AI opportunity is therefore not unrestricted consumer growth automation. It is better regulatory intelligence, product and pack control, manufacturing quality, supply-chain traceability, age-compliance operations, and governed portfolio execution across a changing category.

Value chain

• Portfolio, Regulation & Product Architecture: Managing cigarettes, heated tobacco, vaping products, nicotine pouches and other regulated nicotine formats as distinct product architectures, with clear market definitions, product status, applicable rules, notification pathways, tax treatment, age restrictions, technical evidence and approved use boundaries.
• Product Development, Science & Technical Evidence: Managing device and consumable specifications, formulations, materials, ingredients, nicotine content, emissions or aerosol evidence where relevant, testing, stability, battery or electrical considerations, supplier inputs, technical files, product claims and change control before market release.
• Manufacturing, Quality & Device or Consumable Assurance: Managing automated production, filling, pouch manufacture, tobacco processing, device assembly, quality inspection, laboratory evidence, equipment condition, deviations, supplier quality, nonconformance, maintenance, batch or lot identity, and product-release records.
• Product Data, Packaging, Notification & Tax: Maintaining approved product master data, pack configurations, health or warning requirements, instructions, identifiers, ingredients or emissions records, market notifications, security features, tax or duty status, version control and effective dates across jurisdictions.
• Track, Trace, Distribution & Controlled Retail: Managing tobacco track-and-trace obligations where applicable, facility and economic-operator identity, shipment events, warehouse movements, authorised channels, excise records, retail requirements, age controls, and suspicious or incomplete supply-chain records.
• Post-Market, Compliance & Portfolio Governance: Managing complaints, adverse or safety signals, regulator correspondence, market surveillance, illicit-product intelligence, retailer compliance, age-assurance performance, product changes, withdrawals, corrective actions, portfolio reviews, audit evidence and AI governance across product categories.

Where AI may help

• Cross-category regulatory intelligence: Helping teams retrieve and compare current tobacco, vaping, heated-tobacco and nicotine-product rules, effective dates, notification requirements, age restrictions, packaging obligations, tax or excise changes and regulator correspondence by market while keeping legal interpretation and final compliance decisions with accountable specialists.
• Technical and product evidence retrieval: Helping R&D, quality and regulatory teams search approved specifications, test reports, supplier files, device records, formulation information, scientific evidence, prior submissions and change histories so product questions can be answered from controlled sources rather than fragmented files.
• Manufacturing quality and predictive maintenance: Using approved process, equipment, sensor, alarm, quality, defect, laboratory and maintenance data to identify abnormal patterns, recurring defects or likely asset issues across tobacco, pouch, vapour or device operations while keeping technical intervention and product release human-led.
• Product, pack and notification control: Helping teams compare approved product master data, artwork, warnings, identifiers, technical information, market notifications, tax status and effective dates to flag inconsistent or outdated records before manufacture, shipment or release.
• Track-and-trace and excise reconciliation: Helping teams reconcile approved identifier, facility, scan, shipment, warehouse, movement and tax records to identify missing events, duplicates, unexpected routes or reconciliation gaps requiring investigation without treating anomalies as proof of misconduct.
• Age-assurance and post-market compliance support: Helping teams organise age-control procedures, retailer guidance, system-performance evidence, complaints, market-surveillance findings, illicit-product reports, training and compliance records while preserving privacy, lawful use, human escalation and a strict prohibition on youth targeting or unlawful promotion.

Business Outcomes

AI should be judged by whether a defined tobacco or nicotine-product workflow improves in measurable ways such as faster regulatory change assessment, fewer product-data errors, quicker technical evidence retrieval, clearer quality investigation, stronger traceability reconciliation, or better post-market compliance visibility without weakening age restrictions, tobacco-control obligations, product safety, excise, legal claims, privacy, or accountable human judgement.

• Regulatory teams must track different and changing rules across cigarettes, heated tobacco, vaping products and oral nicotine formats Productivity improvement: Faster comparison of approved regulatory sources, effective dates and product-category obligations Impact: More specialist time available for interpretation, impact assessment and implementation planning Example outcome: Better-prepared regulatory-change and market-readiness decisions
• Product and technical evidence can be fragmented across R&D, suppliers, quality, regulatory systems and historical submissions Productivity improvement: Faster retrieval and comparison of approved product and technical records Impact: More expert time available for validation, testing and material technical questions Example outcome: Better-prepared product-development and submission reviews
• Fast product cycles can create version-control risk across devices, consumables, packs, warnings, notifications and product master data Productivity improvement: Earlier identification of mismatched, incomplete or outdated approved product records Impact: Less avoidable rework and lower risk of releasing the wrong product or pack configuration Example outcome: Better-prepared product-data, packaging and notification controls
• Multi-category supply chains can create complex movement, traceability, excise and authorised-channel exceptions Productivity improvement: Faster reconciliation of approved movement, identifier and tax records Impact: More compliance attention on material exceptions rather than manual data assembly Example outcome: Better-prepared traceability, excise and anti-illicit-trade investigations
• AI use can create serious risk if it is applied to youth targeting, addictive-use optimisation, unlawful promotion, unsupported health or reduced-risk claims, age-control circumvention, excise evasion or regulatory avoidance Productivity improvement: Defined prohibited uses, role-based access, approved sources, legal review, age and audience controls, claim governance, model validation, logging, monitoring, escalation and accountable approval Impact: More controlled AI adoption across a rapidly changing regulated portfolio Example outcome: More consistent transition from isolated automation to governed multi-category operations

SXNTH.AI® Approach

SXNTH.AI® starts with one real tobacco or nicotine-product workflow rather than a list of AI tools. We observe how the work happens today, identify where regulatory change, product evidence, version control, quality investigation, traceability reconciliation, age-assurance operations, or post-market compliance creates measurable friction, shape the smallest useful AI-supported workflow, and test it with the regulatory, R&D, manufacturing, quality, supply-chain, tax, retail-compliance or governance teams who will use it. The result is evidence about what worked, what did not, and what should happen next before anything is scaled.

Capabilities applied to this vertical

For tobacco and nicotine-product businesses, these capabilities come together around product-category definitions, regulatory change, technical and scientific evidence, manufacturing and device data, product master data, notifications, packaging, excise, track and trace, age restrictions, post-market controls, privacy, prohibited uses, model validation, cybersecurity, staff capability and practical measurement. Technology follows the regulated operational problem and the consequence of the decision rather than leading the engagement.

• AI Strategy & Opportunity Design
• AI Quality Assurance, Governance & Risk
• Adoption, Enablement & Operational Readiness

Boundaries

SXNTH.AI® does not support AI intended to increase nicotine uptake, target minors or vulnerable audiences, optimise addictive use, circumvent age controls, facilitate unlawful promotion, weaken required warnings, evade excise or traceability, or generate unsupported health, cessation or reduced-risk claims. SXNTH.AI® also does not replace product-notification responsibility, legal interpretation, scientific or technical sign-off, quality release, tax authority, age-verification responsibility, regulator engagement, withdrawal or corrective-action authority, or formal compliance assurance. AI can support retrieval, reconciliation, analysis, drafting, prediction and evidence organisation, but consequential outputs should be checked against current law, approved product records, original evidence and accountable specialist judgement.

Regulation, Governance & Risk Built In

Tobacco and nicotine-product environments can combine cigarette and heated-tobacco records, vaping devices and consumables, nicotine-pouch specifications, formulations, ingredients, device and battery information, scientific evidence, manufacturing data, product notifications, pack artwork, warnings, identifiers, excise records, track-and-trace scans, retailer compliance, age-assurance evidence, complaints, market-surveillance findings and regulator correspondence. AI use should therefore be designed around approved sources, product-category identity, market and effective date, strict access controls, age and audience restrictions, claims governance, traceability, privacy, model validation, prohibited-use rules, cybersecurity and accountable ownership of regulated decisions.

We consider the lawful and ethical purpose of the use case, the product category and market, whether the workflow could influence nicotine uptake or youth access, current notification and packaging rules, technical and scientific evidence, age restrictions, tax and traceability obligations, device and product-safety information, model performance, source provenance, retailer and supplier interfaces, incident escalation, audit evidence, monitoring and accountable review. The control model should be proportionate to the public-health, consumer, regulatory, financial, legal and reputational consequence of the task.

Map your first governed AI workflow

We'll work through one real tobacco or nicotine-product workflow with you, from the friction point and data flow to product-category rules, technical evidence, age controls, prohibited uses, validation, human review, auditability and a practical AI-supported test, at no commitment.

Assess your AI Readiness

Take the short AI Maturity Quiz to see where your organisation stands today and where the practical next steps lie.

Frequently asked questions

• Q: Should this sector still be called tobacco? A: Not on its own. Cigarettes and other tobacco products remain material, but leading manufacturers and regulators now operate across multiple categories including heated tobacco, vaping and nicotine products such as pouches. 'Tobacco & Nicotine Products' is a broader and more neutral umbrella. 'New Generation Products' or 'NGPs' can remain useful industry terminology in body copy and SEO, but it is less precise as the primary page title because definitions vary by company and jurisdiction. Related: AI Starts with Use Cases
• Q: Where is AI most useful across tobacco and newer nicotine products? A: Useful areas to investigate include regulatory intelligence, technical-evidence retrieval, manufacturing quality, predictive maintenance, product and pack version control, notifications, traceability, excise reconciliation, supplier assurance, age-control operations and post-market compliance. Current BAT and PMI disclosures show non-combustible categories becoming more material to their businesses, while UK regulation increasingly treats tobacco, vaping and nicotine products through distinct product rules. Related: AI Quality Assurance
• Q: Can AI manage product notifications and packaging rules? A: AI can help retrieve current requirements, compare approved product and pack data, flag missing evidence and prepare first-pass submission or review material. It should not approve a notification, warning, device, formulation, health claim or market release. Requirements differ by product and jurisdiction and can change quickly, so final interpretation and sign-off remain accountable specialist responsibilities. Related: AI Governance
• Q: Can AI be used to support age assurance? A: AI can support age-assurance operations where lawful, including system testing, exception handling, evidence retrieval and performance monitoring. It should not be assumed to remove retailer or operator responsibility. Age-estimation and verification can create privacy, accuracy, bias and false-rejection issues, and the UK Tobacco and Vapes Act 2026 adds new age rules for vaping and nicotine products from 29 October 2026. Related: Information Security Policy
• Q: Should SXNTH position NGPs as safer or reduced-risk products? A: No blanket claim should be made. Product risk, legal status and permitted claims vary by product and regulator. Company terms such as 'smoke-free' or 'new categories' can be attributed to the company using them, but SXNTH should use neutral language such as vaping products, heated tobacco, nicotine pouches, oral nicotine or non-combustible products unless a specific regulated claim is being cited accurately. Related: AI Governance
• Q: How should a tobacco and nicotine-product business start with AI? A: Choose one bounded operational or compliance workflow where regulatory change, product evidence, version control, quality investigation, traceability, excise, age assurance or post-market review creates measurable friction. Establish the current baseline, identify authoritative sources and product categories, define prohibited uses and legal boundaries, and test the smallest useful intervention before expanding into higher-consequence regulated decisions. Related: AI Maturity Quiz

Get in Touch

Ready to improve a tobacco or nicotine-product workflow with AI?

We help regulated tobacco and nicotine-product businesses test practical AI around real regulatory, technical, manufacturing, product-data, quality, traceability, excise and compliance workflows while keeping public-health safeguards, age restrictions, governance and human accountability explicit.